Brokerages expect that Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) will post earnings of ($1.41) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Alder BioPharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.97) and the highest estimate coming in at ($1.12). Alder BioPharmaceuticals posted earnings of ($0.70) per share during the same quarter last year, which would indicate a negative year over year growth rate of 101.4%. The firm is expected to issue its next earnings report on Thursday, October 26th.
On average, analysts expect that Alder BioPharmaceuticals will report full year earnings of ($6.35) per share for the current fiscal year, with EPS estimates ranging from ($7.91) to ($5.40). For the next year, analysts anticipate that the firm will post earnings of ($4.35) per share, with EPS estimates ranging from ($6.84) to ($3.56). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Alder BioPharmaceuticals.
Alder BioPharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.67) by $0.19. The business had revenue of $0.68 million during the quarter. The company’s revenue for the quarter was up 518.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.79) earnings per share.
Several equities research analysts have recently commented on the company. Leerink Swann reissued an “outperform” rating and set a $32.00 price target on shares of Alder BioPharmaceuticals in a research note on Monday, June 12th. Needham & Company LLC set a $36.00 price target on Alder BioPharmaceuticals and gave the stock a “buy” rating in a research note on Monday, July 17th. Zacks Investment Research lowered Alder BioPharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday. UBS AG assumed coverage on Alder BioPharmaceuticals in a research note on Friday, May 5th. They set a “sell” rating and a $13.00 price target on the stock. Finally, ValuEngine lowered Alder BioPharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, June 29th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $33.75.
In other Alder BioPharmaceuticals news, Director Stephen M. Dow purchased 25,000 shares of the business’s stock in a transaction on Tuesday, July 18th. The stock was bought at an average cost of $10.00 per share, for a total transaction of $250,000.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 10.60% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Redmile Group LLC increased its position in shares of Alder BioPharmaceuticals by 107.5% in the first quarter. Redmile Group LLC now owns 1,909,886 shares of the biopharmaceutical company’s stock valued at $39,726,000 after buying an additional 989,336 shares during the period. Eagle Asset Management Inc. increased its position in shares of Alder BioPharmaceuticals by 52.0% in the second quarter. Eagle Asset Management Inc. now owns 1,756,507 shares of the biopharmaceutical company’s stock valued at $20,112,000 after buying an additional 601,242 shares during the period. Emerald Advisers Inc. PA increased its position in shares of Alder BioPharmaceuticals by 98.3% in the second quarter. Emerald Advisers Inc. PA now owns 1,193,672 shares of the biopharmaceutical company’s stock valued at $13,668,000 after buying an additional 591,840 shares during the period. Emerald Mutual Fund Advisers Trust increased its position in shares of Alder BioPharmaceuticals by 125.5% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 942,709 shares of the biopharmaceutical company’s stock valued at $10,794,000 after buying an additional 524,746 shares during the period. Finally, Citadel Advisors LLC increased its position in shares of Alder BioPharmaceuticals by 1,209.4% in the first quarter. Citadel Advisors LLC now owns 467,387 shares of the biopharmaceutical company’s stock valued at $9,722,000 after buying an additional 431,691 shares during the period. Institutional investors own 82.44% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “” was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/08/09/1364509.html.
Alder BioPharmaceuticals (ALDR) traded up 4.89% during trading on Wednesday, reaching $9.65. The company had a trading volume of 1,388,777 shares. The firm has a 50-day moving average of $12.91 and a 200-day moving average of $18.65. The stock’s market capitalization is $486.46 million. Alder BioPharmaceuticals has a 1-year low of $9.40 and a 1-year high of $36.48.
About Alder BioPharmaceuticals
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.